Study of Daily Rifapentine for Pulmonary Tuberculosis
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The goal of this Phase 2 study is to determine the microbiological activity and safety of
rifapentine when given as a component of multidrug intensive phase treatment of
smear-positive pulmonary tuberculosis (TB).
Funding Source- FDA Office of Orphan Products Development (OOPD)
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
University of Cape Town University of Cape Town Lung Institute